ALFA Finder| Revenue growth | 21.9% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA margin improved 190 bps to 22.0%. |
| Demand visibility | Strong, targeting 8-9% IPM CAGR till FY30. |
| Management confidence | High, focused on '3C' philosophy and execution excellence. |
Growth
Revenue grew 21.9% YoY to INR 422.4 Cr; PAT increased 30.1% YoY to INR 60.1 Cr.
Outlook
Focusing on market share expansion in chronic segments and scaling the newly commercialized EU-GMP approved hormone facility.
Risks
Potential impacts from the Indian economy, international market volatility, and intense competition in the pharmaceutical industry.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21.9% (= BEAT)
- Guided 20% PAT growth → delivered 30.1% (= BEAT)
- Guided 80% gross margin → delivered 81.4% (= BEAT)
Partly delivered
- Guided 20% plus EBITDA margin → delivered 22.0% (= BEAT/PARTIAL as Q4 was 17.6%)
Investor Presentation filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,387.30
- Market cap
- ₹14,601 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 70.5×Sector 43.8×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Legal & Regulatory
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
- Value
- ₹4.88 Cr
Corona Remedies Earnings Call Transcript: Key Takeaways
CORONA delivered robust revenue growth of 22% YoY, outperforming the Indian pharmaceutical market by focusing on chronic segments. Management maintains a growth target of 1.5x the market rate.
- Call
- Guides 15% growth
Corona Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹441.2Cr (+22.2%), PAT ₹60.3Cr (+15.3%); H1 revenue ₹863.6Cr (+22.0%), PAT ₹120.4Cr (+22.2%). Chronic-led growth, outpacing IPM.
Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.